ArticlePloS one2017
Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Advances in MicroRNA Therapy for Heart Failure: Clinical Trials, Preclinical Studies, and Controversies.Cardiovascular drugs and therapy · 2025Review
- MicroRNA profiling of the feline left heart identifies chamber-specific expression signatures in health and in advanced hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2023Article
- Systems Biology in Chronic Heart Failure-Identification of Potential miRNA Regulators.International journal of molecular sciences · 2022Article
- Downregulation of ACE, AGTR1, and ACE2 genes mediating SARS-CoV-2 pathogenesis by gut microbiota members and their postbiotics on Caco-2 cells.Microbial pathogenesis · 2022Article
- A practical guide to setting up pig models for cardiovascular catheterization, electrophysiological assessment and heart disease research.Lab animal · 2022Review
- Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers.Frontiers in oncology · 2022Review
- iPSCs and Exosomes: Partners in Crime Fighting Cardiovascular Diseases.Journal of personalized medicine · 2021Review
- Targets and regulation of microRNA-652-3p in homoeostasis and disease.Journal of molecular medicine (Berlin, Germany) · 2021Review
- The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.Cell & bioscience · 2021Article
- Transcriptomic analysis reveals the role of a peptide derived from CRYAB on the CoClJournal of thrombosis and thrombolysis · 2021Article
- Mitochondrial CaJournal of molecular and cellular cardiology · 2021Review
- H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts.Clinical epigenetics · 2020Article
- Review
- MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target.Frontiers in cardiovascular medicine · 2020Review
- Integrative System Biology Analyses Identify Seven MicroRNAs to Predict Heart Failure.Non-coding RNA · 2019Article
- Construction and analysis of the lncRNA‑miRNA‑mRNA network based on competitive endogenous RNA reveals functional genes in heart failure.Molecular medicine reports · 2019Article
- Systematic dissection, preservation, and multiomics in whole human and bovine hearts.Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyArticle
- Correlations of circulating miR-26b level with left ventricular hypertrophy and cardiac function in elderly patients with hypertension.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe recently identified a set of plasma microRNAs (miRNAs) that are downregulated in patients with heart failure in comparison with control subjects. To better understand their meaning and function, we sought to validate these circulating miRNAs in 3 different well-established rat and mouse heart failure models, and correlated the miRNAs to parameters of cardiac function.
methodsThe previously identified let-7i-5p, miR-16-5p, miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-199a-3p, miR-223-3p, miR-423-3p, miR-423-5p and miR-652-3p were measured by means of quantitative real time polymerase chain reaction (qRT-PCR) in plasma samples of 8 homozygous TGR(mREN2)27 (Ren2) transgenic rats and 8 (control) Sprague-Dawley rats, 6 mice with angiotensin II-induced heart failure (AngII) and 6 control mice, and 8 mice with ischemic heart failure and 6 controls. Circulating miRNA levels were compared between the heart failure animals and healthy controls.
resultsRen2 rats, AngII mice and mice with ischemic heart failure showed clear signs of heart failure, exemplified by increased left ventricular and lung weights, elevated end-diastolic left ventricular pressures, increased expression of cardiac stress markers and reduced left ventricular ejection fraction. All miRNAs were detectable in plasma from rats and mice. No significant differences were observed between the circulating miRNAs in heart failure animals when compared to the healthy controls (all P>0.05) and no robust associations with cardiac function could be found.
conclusionsThe previous observation that miRNAs circulate in lower levels in human patients with heart failure could not be validated in well-established rat and mouse heart failure models. These results question the translation of data on human circulating miRNA levels to experimental models, and vice versa the validity of experimental miRNA data for human heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.